8
7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TQ0111 | LDN-192960 | DYRK , Haspin Kinase | |
LDN-192960 is a potent inhibitor of Haspin and DYRK2 (IC50s: 10 nM and 48 nM). | |||
T9521 | CHR-6494 TFA | Others | |
CHR-6494 TFA is a potent haspin inhibitor, with an IC50 of 2 nM. It inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be use... | |||
T6745 | 5-Iodotubercidin | 5-ITu,NSC 113939 | Adenosine Receptor |
5-Iodotubercidin (NSC-113939) is a potent adenosine kinase inhibitor with IC50 of 26 nM. It inhibits nucleoside transporter, CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2 and PKC. | |||
T62011 | LDN-209929 dihydrochloride | ||
LDN-209929 dihydrochloride is a potent and selective inhibitor of haspin kinase (IC50= 55 nM). LDN-209929 dihydrochloride shows180-fold selectivity verses DYRK2 (IC50= 9.9 μM). | |||
T24396 | LDN-209929 | LDN-209929 dihydrochloride,LDN209929 dihydrochloride,LDN 209929 dihydrochloride | |
LDN-209929 2HCl is a potent and selective inhibitor of haspin kinase. | |||
T11830 | LDN-192960 hydrochloride | Others | |
LDN-192960 hydrochloride is an inhibitor of Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) and Haspin with IC50s of 48 nM and 10 nM, respectively. | |||
T60477 | Haspin-IN-1 | ||
Haspin-IN-1 (compound 2a) is an inhibitor of haspin (haploid germ cell-specific nuclear protein kinase) with an IC50 of 119 nM. Haspin-IN-1 also inhibits CLK1, DYRK1A, and CDK9 with IC50 of 221 nM, 916.3 nM, and 406.8 nM... | |||
T62417 | MELK-8a | ||
MELK-8a (NVS-MELK8a) is a potent and selective inhibitor of maternal embryonic leucine elongation kinase (MELK) (IC50: 2 nM). 0.42 μM). Among them, MELK plays an important role in regulating mitosis in cancer cells. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04774 | ALK-2/ACVR1 Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-01096 | ALK-2/ACVR1 Protein, Mouse, Recombinant (His & hFc) | Mouse | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-03707 | ALK-2/ACVR1 Protein, Canine, Recombinant (His) | Canine | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-03247 | ALK-2/ACVR1 Protein, Cynomolgus, Recombinant (hFc) | Cynomolgus | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-00658 | ALK-2/ACVR1 Protein, Human, Recombinant (His & hFc) | Human | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-03157 | ALK-2/ACVR1 Protein, Rat, Recombinant (hFc) | Rat | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... | |||
TMPY-03706 | ALK-2/ACVR1 Protein, Canine, Recombinant (hFc) | Canine | HEK293 |
ALK-2, also termed as ACVR1, was initially identified as an activin type I receptor because of its ability to bind activin in concert with ActRII or ActRIIB. ALK-2 is also identified as a BMP type I receptor. It has been... |